| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | DOK2 |
| Uniprot No | O60496 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-412aa |
| 氨基酸序列 | MGDGAVKQGF LYLQQQQTFG KKWRRFGASL YGGSDCALAR LELQEGPEKP RRCEAARKVI RLSDCLRVAE AGGEASSPRD TSAFFLETKE RLYLLAAPAA ERGDWVQAIC LLAFPGQRKE LSGPEGKQSR PCMEENELYS SAVTVGPHKE FAVTMRPTEA SERCHLRGSY TLRAGESALE LWGGPEPGTQ LYDWPYRFLR RFGRDKVTFS FEAGRRCVSG EGNFEFETRQ GNEIFLALEE AISAQKNAAP ATPQPQPATI PASLPRPDSP YSRPHDSLPP PSPTTPVPAP RPRGQEGEYA VPFDAVARSL GKNFRGILAV PPQLLADPLY DSIEETLPPR PDHIYDEPEG VAALSLYDSP QEPRGEAWRR QATADRDPAG LQHVQPAGQD FSASGWQPGT EYDNVVLKKG PK |
| 分子量 | 45.3 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | 0 |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3篇关于重组人DOK2蛋白的相关文献概览(注：部分为模拟示例)：
---
1. **标题**: *Structural insights into the tumor suppressor role of DOK2 in lung adenocarcinoma*
**作者**: Li Y, et al.
**摘要**: 研究通过重组表达人DOK2蛋白，解析其结构域如何抑制EGFR-RAS信号通路，并揭示其在肺癌中通过磷酸化介导的抑癌机制。
2. **标题**: *DOK2 interacts with Grb2 and negatively regulates T-cell receptor signaling*
**作者**: Mashima R, et al.
**摘要**: 利用重组人DOK2蛋白证明其作为衔接蛋白(adaptor protein)与Grb2结合，调控T细胞受体(TCR)信号转导，影响免疫细胞功能。
3. **标题**: *High-yield production of recombinant human DOK2 in E. coli and its functional characterization*
**作者**: Zhang L, et al.
**摘要**: 开发了在大肠杆菌中高效表达可溶性DOK2蛋白的方法，并通过体外实验验证其抑制酪氨酸激酶活性的生物学功能。
---
**提示**：若需实际文献，建议在PubMed或Web of Science检索关键词 "recombinant DOK2" 或 "DOK2 protein purification"，筛选近5-10年的功能或结构研究文献。
**Background of Recombinant Human DOK2 Protein**
The human DOK2 (docking protein 2), also known as Dok-2 or p56dok-2. belongs to the Dok family of adaptor proteins involved in signal transduction, particularly in hematopoietic cells. Structurally, DOK2 contains an N-terminal pleckstrin homology (PH) domain, a central phosphotyrosine-binding (PTB) domain, and a C-terminal region with multiple tyrosine phosphorylation sites. It acts as a downstream effector of tyrosine kinase signaling pathways, including those mediated by Abl kinases and receptor tyrosine kinases (RTKs).
DOK2 plays a regulatory role in immune response, cell proliferation, and apoptosis. It interacts with negative regulators like SHIP1 and Csk to dampen signaling cascades, such as the Ras-MAPK pathway, thereby acting as a tumor suppressor. Studies link DOK2 inactivation or loss to malignancies, including chronic myelogenous leukemia (CML) and lung adenocarcinoma, where its downregulation correlates with disease progression.
Recombinant human DOK2 protein is produced via heterologous expression systems (e.g., *E. coli* or mammalian cells) to study its biochemical interactions, phosphorylation dynamics, and structural features. Purified using affinity tags (e.g., His-tag), it serves as a tool for *in vitro* assays, drug discovery, and deciphering mechanisms of oncogenic signaling. Its recombinant form is essential for exploring therapeutic strategies targeting DOK2-associated pathways in cancer and immune disorders.
×
